In Competition Law and Policy Debate, Raphaël De Coninck highlights the European Commission’s recent interest in assessing the impact of pharmaceutical mergers on innovation. The article discusses the Commission’s approach and argues in favor of developing a consistent framework for assessing the impact of mergers on innovations. To read more, click the link below.
Aggregate royalty for cellular SEPs in recent court decisions
This academic paper, “Aggregate Royalty for Cellular SEPs in Recent Court Decisions,” published in GRUR Patent by CRA Competition experts Nadia Soboleva and...